Boehringer v. JAMP continued: the Federal Court’s look at anticipation and sound prediction of utility
The Federal Court’s recent decision in Boehringer v JAMP, 2024 FC 1198 concerned two patents relating to nintedanib capsules (which Boehringer markets...Read More
An essential part of construction: Federal Court revisits the test for whether a claim element is essential or non-essential
Boehringer v JAMP, 2024 FC 1198 was an action under the PMNOC Regulations concerning infringement and validity of two patents relating to...Read More
Leave Granted to Amend Statement of Defence and Includes Bases of Invalidity not Contained in Notice of Allegation
In Boehringer Ingelheim (Canada) Ltd v JAMP Pharma Corporation, 2023 FC 1414, Associate Judge Cotter of the Federal Court granted JAMP’s motion...Read More
An Illuminating Decision on Induced Infringement from the Federal Circuit
Background The Court of Appeals for the Federal Circuit reversed the District Court of Delaware’s decision holding Roche Diagnostics Corporation induced infringement...Read More
FDA’s biosimilar stakeholder submission roundup – Part III
In March 2010, the Biologics Price Competition and Innovation Act of 2009 (BPCIA) became law and established a legal pathway for the...Read More